Source study found

Story checked

Use of MRI before prostate biopsies increases sharply across U.S. hospitals (opens in a new tab)

medicalxpress.com · 2026-09-20

Short answerEvidenceSource

Short answer

Not supported

Not supported.

The study does not answer the story's main claims.

6 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Use of MRI before prostate biopsies increases sharply across U.S. hospitals

medicalxpress.com · 2026-09-20

The story’s checkable claims.

Read the original story

NewsLink checks it

Not supported

The study doesn't address any of the story's claims. We found the paper, but it doesn't report the details the story leads with.

6 not covered

Open claim evidence

The source study

Trends in Prebiopsy MRI Utilization for Prostate Cancer Detection

JAMA Oncology · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredUsing prostate MRI before a biopsy is a real advance in prostate cancer diagnosis, and multiple randomized trials have shown that imaging the prostate first and then targeting suspicious lesions finds more of the aggressive cancers that matter.View evidenceHide evidence

Why this verdict

The abstract-level paper profile identifies the study as an observational utilization-trend analysis of prebiopsy prostate MRI, not an efficacy study of MRI-targeted biopsy. Claims about randomized trials, diagnostic superiority, and finding more aggressive cancers may be background context, but they are not verifiable from the supplied abstract profile.

Study evidence

The study evaluates rates and temporal trends in prebiopsy MRI use among US men undergoing evaluation that led to prostate biopsy between January 2017 and June 2026; the abstract does not report the observed utilization rates or trend estimates.

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Claim 2 of 6Not coveredA new study released Sept. 17 in JAMA Oncology looked at more than 505,000 prostate biopsies performed at U.S. hospitals between January 2017 and June 2026 using Epic Cosmos, a database drawn from electronic health records across many health systems.View evidenceHide evidence

As statedmore than 505,000 biopsies

Why this verdict

The abstract profile supports that the paper is a US cohort study of prebiopsy prostate MRI use from January 2017 through June 2026 among men undergoing prostate biopsy evaluation. However, the supplied profile does not verify the JAMA Oncology release date, Epic Cosmos as the data source, hospital/EHR coverage details, or the stated sample size of more than 505,000 biopsies.

Study evidence

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Claim 3 of 6Not coveredAmong men getting their first biopsy, prebiopsy MRI use rose from 14% in 2017 to 64% in the first half of 2026.View evidenceHide evidence

As stated14% to 64%

Why this verdict

The paper profile says the study evaluates temporal trends in prebiopsy MRI use, but the abstract-level evidence explicitly lacks numerical utilization estimates. The specific first-biopsy increase from 14% in 2017 to 64% in early 2026 is therefore not verifiable at this depth.

Study evidence

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Claim 4 of 6Not coveredFor men who had a prior negative biopsy, prebiopsy MRI use rose from 38% to 67%.View evidenceHide evidence

As stated38% to 67%

Why this verdict

The supplied abstract profile contains no numeric results and does not report a prior-negative-biopsy subgroup estimate. The stated rise from 38% to 67% cannot be verified from the provided abstract-level evidence.

Study evidence

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Claim 5 of 6Not coveredResearchers said the timing of the shift tracks closely with publication of major trials and incorporation of their results into guidelines, and they also reported that MRI use fell off in men with very high PSA levels and in men over 80.View evidenceHide evidence

Why this verdict

The abstract profile supports only that the study examined US temporal trends in prebiopsy MRI use. It does not report analyses tying the timing to randomized trials or guidelines, nor does it report subgroup findings for very high PSA levels or men over 80.

Study evidence

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Claim 6 of 6Not coveredThe article says a third of men undergoing a first prostate biopsy are still not getting an MRI beforehand, and it describes this as a national problem with access and insurance-coverage issues, plus ongoing concerns about MRI quality.View evidenceHide evidence

As stateda third

Why this verdict

The abstract profile does not provide the proportion of first-biopsy patients without prebiopsy MRI and does not address access, insurance coverage, or MRI quality. These may be interpretation or commentary, but they are not verifiable from the supplied abstract-level paper evidence.

Study evidence

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

At abstract depth, the paper profile does not report numerical utilization rates, sample size, subgroup estimates, confidence intervals, or detailed analytic methods.
The story presents specific numerical rates, subgroup findings, and a sample size as study results, but the supplied abstract-level profile cannot verify these details. This is an evidence-depth limitation rather than necessarily an error in the full article.
From Retrospective cohort using routinely collected healthcare data
The abstract profile does not specify the exact data source, so data-source representativeness and population coverage are uncertain at this depth.
The story names Epic Cosmos and characterizes it as EHR data across many health systems. The supplied paper profile says only that routinely collected healthcare data are implied and explicitly lists the specific data source as unclear from the abstract.
From Retrospective cohort using routinely collected healthcare data

2 things the story did carry across

The paper's central contribution is to quantify temporal trends in prebiopsy prostate MRI utilization in the US from January 2017 to June 2026 among men undergoing evaluation leading to prostate biopsy for cancer detection.
The study is observational and retrospective, using routinely collected healthcare data rather than prospective randomization.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataQuantify temporal trends in prebiopsy prostate MRI utilization in the US (Jan 2017–Jun 2026) among men undergoing evaluation leading to prostate biopsy for cancer detection.Retrospective cohort using routinely collected healthcare dataExpand

In plain English

Retrospective cohort study using US routinely collected healthcare data to quantify temporal trends in use of magnetic resonance imaging (MRI) prior to prostate biopsy for cancer detection between January 2017 and June 2026. The abstract states the study design, objective, setting, and time window but does not provide numerical utilization estimates, sample size, or analytic details.

Key findings

The study evaluates rates and temporal trends in prebiopsy MRI use among US men undergoing evaluation that led to prostate biopsy between January 2017 and June 2026; the abstract does not report the observed utilization rates or trend estimates.

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

What this piece can’t prove

Summary is based on title and single-sentence abstract; no numeric results or methodological details are available in the provided text.
Unclear which routinely collected data source was used (claims vs EHR vs registry) and therefore uncertain generalizability and population coverage.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer